Bordetella pertussis: Why is it still circulating?

Journal of Infection

Volumn 68, Issue SUPPL1, 2014, Pages

  Guiso, Nicole ^a,b  

^a INSTITUT PASTEUR   (France)

^b CNRS   (France)

Author keywords

Bordetella pertussis; Diagnostic; Vaccine; Whooping cough

Indexed keywords

CYTOTOXIN; FIMBRIA PROTEIN; HEMAGGLUTININ; HEMOLYSIN; PERTACTIN; PERTUSSIS TOXIN; PERTUSSIS VACCINE;

ARTICLE; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BACTERIUM DETECTION; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; BORDETELLA PERTUSSIS; DIAGNOSTIC PROCEDURE; DISEASE ACTIVITY; DISEASE SURVEILLANCE; DRUG DESIGN; DRUG DEVELOPMENT; DRUG EFFICACY; HERD IMMUNITY; INFECTION SENSITIVITY; INNATE IMMUNITY; MASS IMMUNIZATION; MOLECULAR EVOLUTION; PERTUSSIS; POLYMERASE CHAIN REACTION; VACCINATION; VACCINE PRODUCTION;

BORDETELLA PERTUSSIS; DIAGNOSTIC; VACCINE; WHOOPING COUGH;

BORDETELLA PERTUSSIS; HUMANS; INFANT; PERTUSSIS VACCINE; WHOOPING COUGH;

EID: 84889654110     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2013.09.022     Document Type: Article

References (43)

1. World Health Organisation Pertussis vaccine: who position paper. Wkly Epidemiol Rec 2010, 40:385-400.
2. Lapin J.H. Whooping cough 1943, Charles C. Thomas, Springfield, IL. 1 ed.
3. Bordet J., Gengou O. Le microbe de la coqueluche. Ann Inst Pasteur 1906, 20:731-741.
4. Eldering G., Kendrick P. Bacillus parapertussis: a species resembling both Bacillus pertussis and Bacillus bronchiseptica, but identical with neither. J Bacteriol 1938, 35:561-572.
5. Bordet J., Gengou O. Note complémentaire sur le microbe de la coqueluche. Ann Inst Pasteur 1907, 21:720-726.
6. Edwards K.M., Decker M.D. Pertussis vaccine. Vaccines 2004, 471-528. Saunders, Philadelphia. 4th ed. S. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
7. Mattoo S., Cherry J.D. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 2005, 18:326-382.
8. Campbell H., Amirthalingam G., Andrews N., Fry N.K., George R.C., Harrison T.G., et al. Accelerating control of pertussis in England and Wales. Emerg Infect Dis 2012, 18:38-47.
9. Grimprel E., Baron S., Levy-Bruhl D., Garnier J.M., Njamkepo E., Guiso N., et al. Influence of vaccination coverage on pertussis transmission in France. Lancet 1999, 354:1699-1700.
10. Zepp F., Heininger U., Mertsola J., Bernatowska E., Guiso N., Roord J., et al. Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect Dis 2011, 11:557-570.
11. Wendelboe A.M., Van Rie A., Salmaso S., Englund J.A. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 2005, 24:S58-S61.
12. Grimprel E., Begue P., Anjak I., Njamkepo E., Francois P., Guiso N. Long-term human serum antibody responses after immunization with whole-cell pertussis vaccine in France. Clin Diagn Lab Immunol 1996, 3:93-97.
13. Anonymous Calendrier vaccinal 2008-Avis du Haut conseil de la santé publique. Bull Epidemiol Heb 2008, 16-17:1-20.
14. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months. MMWR 2011, 60:1424-1426. Advisory Committee on Immunization Practices (ACIP).
15. Lasserre A., Laurent E., Turbelin C., Hanslik T., Blanchon T., Guiso N. Pertussis incidence among adolescents and adults surveyed in general practices in the Paris area, France, May 2008 to March 2009. Euro Surveill 2011, 16. pii=19783.
16. Gilberg S., Njamkepo E., Du Chatelet I.P., Partouche H., Gueirard P., Ghasarossian C., et al. Evidence of Bordetella pertussis infection in adults presenting with persistent cough in a French area with very high whole-cell vaccine coverage. J Infect Dis 2002, 186:415-418.
17. Belchior E., Bonmarin I., Guillot S., Savitch Y., Levy-Bruhl D., Guiso N., et al. Whooping cough surveillance in French hospital Renacoq net: data from 1996 to 2010. 30th annual meeting of the European Society for paediatric infectious diseases. Tessaloniki, Greece 2012, [Poster session].
18. Cherry J.D., Tan T., Wirsing von Konig C.H., Forsyth K.D., Thisyakorn U., Greenberg D., et al. Clinical definitions of pertussis: summary of a global pertussis initiative roundtable meeting, February 2011. Clin Infect Dis 2012, 54:1756-1764.
19. Miranda C., Porte L., Garcia P. Bordetella holmesii in nasopharyngeal samples from Chilean patients with suspected Bordetella pertussis infection. J Clin Microbiol 2012, 50:1505. author reply 6.
20. Njamkepo E., Bonacorsi S., Debruyne M., Gibaud S.A., Guillot S., Guiso N. Reply to Bordetella holmesii in nasopharyngeal samples from Chilean patients with suspected Bordetella pertussis infection. J Clin Microbiol 2012, 50:1506.
21. Guiso N. What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories. Eur J Clin Microbiol Infect Dis 2011, 30:307-312.
22. Riffelmann M., Thiel K., Schmetz J., Wirsing von Koenig C.H. Performance of commercial enzyme-linked immunosorbent assays for detection of antibodies to Bordetella pertussis. J Clin Microbiol 2010, 48:4459-4463.
23. Guillot S., Descours G., Gillet Y., Etienne J., Floret D., Guiso N. Macrolide-resistant Bordetella pertussis infection in newborn girl, France. Emerg Infect Dis 2012, 18:966-968.
24. Mooi F.R., He Q., Guiso N. Phylogeny, evolution, and epidemiology of Bordetellae. Bordetella: molecular microbiology 2007, 17-45. Horizon Bioscience, Norfolk, United Kingdom. C. Locht, INSERM U629 and Institut Pasteur de Lille F (Ed.).
25. Guiso N. Isolation, identification and characterization of Bordetella pertussis 1997, Karger, Basel.
26. Baron S., Njamkepo E., Grimprel E., Begue P., Desenclos J.C., Drucker J., et al. Epidemiology of pertussis in French hospitals in 1993 and 1994: thirty years after a routine use of vaccination. Pediatr Inf Dis J 1998, 17:412-418.
27. Njamkepo E., Cantinelli T., Guigon G., Guiso N. Genomic analysis and comparison of Bordetella pertussis isolates circulating in low and high vaccine coverage areas. Microbes Infect 2008, 10:1582-1586.
28. Weber C., Boursaux-Eude C., Coralie G., Caro V., Guiso N. Polymorphism of Bordetella pertussis isolates circulating the last ten years in France, where a single effective whole-cell vaccine has been used for more than thirty years. J Clin Microbiol 2001, 39:4396-4403.
29. Guiso N. Bordetella pertussis and pertussis vaccines. Clin Infect Dis 2009, 49:1565-1569.
30. Hegerle N., Paris A.S., Brun D., Dore G., Njamkepo E., Guillot S., et al. Evolution of French Bordetella pertussis and Bordetella parapertussis isolates: increase of Bordetellae not expressing pertactin. Clin Microbiol Infect 2012, 18:E340-E346.
31. Stefanelli P., Fazio C., Fedele G., Spensieri F., Ausiello C.M., Mastrantonio P. A natural pertactin deficient strain of Bordetella pertussis shows improved entry in human monocyte-derived dendritic cells. New Microbiol 2009, 32:159-166.
32. Bouchez V., Brun D., Cantinelli T., Dore G., Njamkepo E., Guiso N. First report and detailed characterization of B. pertussis isolates not expressing Pertussis Toxin or Pertactin. Vaccine 2009, 27:6034-6041.
33. Barkoff A.M., Mertsola J., Guillot S., Guiso N., Berbers G., He Q. Appearance of Bordetella pertussis strains not expressing vaccine antigen pertactin in Finland. Clin Vaccine Immunol 2012;19:1703-4.
34. Otsuka N., Han H.J., Toyoizumi-Ajisaka H., Nakamura Y., Arakawa Y., Shibayama K., et al. Prevalence and genetic characterization of pertactin-deficient Bordetella pertussis in Japan. PLoS One 2012, 7:e31985.
35. Bouchez V., Brun D., Dore G., Njamkepo E., Guiso N. Bordetella parapertussis isolates not expressing pertactin circulating in France. Clin Microbiol Infect 2011, 17:675-682.
36. Kurova N., Njamkepo E., Brun D., Tseneva G., Guiso N. Monitoring of Bordetella isolates circulating in Saint Petersburg, Russia between 2001 and 2009. Res Microbiol 2010, 161:810-815.
37. Beytout J., Launay O., Guiso N., Fiquet A., Baudin M., Richard P., et al. Safety of Tdap-IPV given one month after Td-IPV booster in healthy young adults: a placebo- controlled trial. Hum Vaccine 2009, 5:315-321.
38. Halperin S.A., Scheifele D., De Serres G., Noya F., Meekison W., Zickler P., et al. Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous dose. Vaccine 2012, 30:974-982.
39. Diavatopoulos D.A., Cummings C.A., Schouls L.M., Brinig M.M., Relman D.A., Mooi F.R. Bordetella pertussis, the causative agent of whooping cough, evolved from a distinct, human-associated lineage of B. bronchiseptica. PLoS Pathog 2005, 1:373-383.
40. Gueirard P., Weber C., Le Coustumier A., Guiso N. Human Bordetella bronchiseptica infection related to contact with infected animals: persistence of bacteria in host. J Clin Microbiol 1995, 33:2002-2006.
41. Betsou F., Sebo P., Guiso N. The C-terminal domain is essential for protective activity of the Bordetella pertussis adenylate cyclase-hemolysin. Infect Immun 1995, 63:3309-3315.
42. Carbonetti N.H. Pertussis toxin and adenylate cyclase toxin: key virulence factors of Bordetella pertussis and cell biology tools. Future Microbiol 2010, 5:455-469.
43. Khelef N., Zychlinsky A., Guiso N. Bordetella pertussis induces apoptosis in macrophages: role of adenylate cyclase-hemolysin. Infect Immun 1993, 61:4064-4071.